Clinical Trials

129 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03174275 2026-02-23

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

GastrointestinalHead & Neck

39 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Esophageal Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03258554 2026-02-06

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Phase 2/3 Completed

196 enrolled 31 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

40 enrolled

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03381183 2025-12-05

IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

19 enrolled

Phase 1 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

120 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03739931 2025-08-15

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

134 enrolled

Head & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Lymphoma

NCT03635164 2025-06-27

Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma

21 enrolled

Phase EARLY_PHASE1 Completed

Squamous Cell Carcinoma of Head and Neck

NCT03618654 2025-05-15

Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma

38 enrolled

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck

NCT03212469 2025-05-08

ABIMMUNE

Phase 1/2 Completed

54 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Neoplasms, Lung Neoplasms

NCT03726775 2025-05-07

REWRITe

61 enrolled

Phase EARLY_PHASE1 Terminated

Squamous Cell Carcinoma of Head and Neck

NCT02827838 2025-03-17

Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer

17 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck, Papillomavirus Infections

NCT03509012 2025-01-14

CLOVER

Phase 1/2 Active not recruiting

105 enrolled

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT03784066 2024-07-03

DUTRELASCO

21 enrolled

Phase 1/2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT03283605 2024-06-28

Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas

45 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT06446570 2024-06-06

Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma

18 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03723967 2024-04-22

FRAIL-IMMUNE

104 enrolled

Squamous Cell Carcinoma of Head and Neck, Recurrence

NCT03618134 2023-11-18

Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

Phase 1/2 Terminated

19 enrolled

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms

NCT03088059 2023-11-03

UPSTREAM

Phase 2 Unknown

340 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03624231 2023-08-31

DURTRE-RAD

18 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03522584 2023-06-12

Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1/2 Terminated

6 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck

NCT04359199 2023-02-10

QUASAR

Unknown

42 enrolled

BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Deglutition Disorders, Head and Neck Neoplasms, Oropharyngeal Neoplasms

NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Phase 1/2 Completed

58 enrolled 24 charts

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

NCT03162224 2022-08-25

Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

Phase 1/2 Completed

35 enrolled 25 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT03292250 2022-03-29

Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]

180 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03799744 2022-03-28

Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma

Phase 1 Unknown

20 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT02551159 2021-10-13

KESTREL

Phase 3 Completed

823 enrolled 23 charts

Squamous Cell Carcinoma of Head and Neck

NCT03450967 2021-08-10

Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC

Phase 2 Unknown

31 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03673735 2021-05-10

ADHERE

Phase 3 Withdrawn

Squamous Cell Carcinoma of Head and Neck

NCT03144778 2021-03-18

Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer

39 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT01938612 2021-03-12

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours

GastrointestinalHead & Neck

269 enrolled

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms

NCT04262388 2020-11-17

DOME

Phase 2 Withdrawn

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors